
    
      The objective of this study is to evaluate the potential of DSXS to suppress HPA axis
      function in patients with moderate to severe atopic dermatitis.

      The secondary objectives are to evaluate to evaluate adverse event (AE) profiles of DSXS
      administered to patients with moderate to severe atopic dermatitis.
    
  